Pinning Hopes On A Wider Offering, Boehringer-Lilly Launch DPP-4 Trajenta In A Crowded India Market
This article was originally published in PharmAsia News
A 30% annual growth in the anti-diabetes market is fueling new launches in India, but competition is getting tougher.
You may also be interested in...
MUMBAI - Explosive growth in India's anti-diabetes medicines market is turning arch rivals into allies. The latest example is of Eli Lilly & Co. combining forces with German giant Boehringer Ingelheim GmbH.
MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments
MUMBAI - In an attempt to add more teeth to its rapidly growing anti-diabetes franchise in India, Merck & Co.'s affiliate MSD India and Sun Pharmaceutical Industries Ltd. jointly announced the formation of an "India-specific strategic partnership" under which Sun will have the right to market, promote and distribute MSD's star products Januvia (sitagliptin) and Janumet (sitagliptlin/metformin) under different brand names